| 1 |
33713009 | SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism. | 2022 May |
1 |
| 2 |
34697809 | Body mass index is inversely associated with capillary ketones at the time of colonoscopy: Implications for SGLT2i use. | 2022 Apr |
4 |
| 3 |
34860594 | Treatments for skeletal muscle abnormalities in heart failure: sodium-glucose transporter 2 and ketone bodies. | 2022 Feb 1 |
1 |
| 4 |
35120993 | The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis. | 2022 Mar |
2 |
| 5 |
35155918 | Breath Analysis for the In Vivo Detection of Diabetic Ketoacidosis. | 2022 Feb 8 |
1 |
| 6 |
35293041 | Diarylcuprates for Selective Syntheses of Multifunctionalized Ketones from Thioesters under Mild Conditions. | 2022 May 6 |
1 |
| 7 |
33404998 | Beneficial effects on kidney during treatment with sodium-glucose cotransporter 2 inhibitors: proposed role of ketone utilization. | 2021 Jul |
3 |
| 8 |
33512450 | SGLT2 Inhibitor-Induced Low-Grade Ketonemia Ameliorates Retinal Hypoxia in Diabetic Retinopathy-A Novel Hypothesis. | 2021 Apr 23 |
1 |
| 9 |
33651228 | Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials. | 2021 Jul |
1 |
| 10 |
33896795 | Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor-Treated Type 2 Diabetes. | 2021 Jun |
1 |
| 11 |
34753480 | Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. | 2021 Nov 9 |
2 |
| 12 |
31361403 | Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study. | 2020 Mar |
1 |
| 13 |
31960270 | Insulin resistance and heart failure during treatment with sodium glucose cotransporter 2 inhibitors: proposed role of ketone utilization. | 2020 May |
1 |
| 14 |
32161953 | Acute Hyperketonemia Does Not Affect Glucose or Palmitate Uptake in Abdominal Organs or Skeletal Muscle. | 2020 Jun 1 |
2 |
| 15 |
32302001 | Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors. | 2020 Aug 1 |
1 |
| 16 |
32358544 | SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. | 2020 May 1 |
1 |
| 17 |
32479196 | Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure. | 2020 Jun 2 |
2 |
| 18 |
32665641 | SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. | 2020 Dec |
1 |
| 19 |
32802705 | Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches. | 2020 Jul |
1 |
| 20 |
32968947 | Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design. | 2020 Nov |
1 |
| 21 |
33230620 | Sodium-Glucose Cotransporter Type 2 (SGLT-2) Inhibitors and Ketogenesis: the Good and the Bad. | 2020 Nov 23 |
1 |
| 22 |
30259621 | Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study. | 2019 Mar |
2 |
| 23 |
31132381 | The combination of exercise training and sodium-glucose cotransporter-2 inhibition improves glucose tolerance and exercise capacity in a rodent model of type 2 diabetes. | 2019 Aug |
1 |
| 24 |
31268032 | [Euglycemic Diabetic Ketoacidosis Caused by a Sodium-glucose Co-transporter (SGLT) 2 Inhibitor after Coronary Artery Bypass Grafting]. | 2019 May |
1 |
| 25 |
31456521 | Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. | 2019 |
1 |
| 26 |
31616297 | Appraisal of Non-Cardiovascular Safety for Sodium-Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials. | 2019 |
1 |
| 27 |
31970162 | SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function. | 2019 |
1 |
| 28 |
29341404 | Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin. | 2018 May |
4 |
| 29 |
29618313 | Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure. | 2018 |
1 |
| 30 |
29899991 | Prolonged diabetic ketoacidosis associated with canagliflozin. | 2018 |
6 |
| 31 |
30073144 | Therapeutic augmentation of ketogenic diet with a sodium-glucose cotransporter 2 inhibitor in a super-refractory status epilepticus patient. | 2018 |
1 |
| 32 |
30073768 | Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component? | 2018 Nov |
3 |
| 33 |
30159178 | Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Presenting with Acute Pancreatitis. | 2018 |
1 |
| 34 |
27878313 | Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. | 2017 Feb |
1 |
| 35 |
28099783 | Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. | 2017 Jul |
1 |
| 36 |
28128510 | Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. | 2017 Jun |
2 |
| 37 |
28178390 | Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. | 2017 Jul |
1 |
| 38 |
28303514 | Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology. | 2017 Apr |
2 |
| 39 |
28325783 | Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes. | 2017 Jun |
1 |
| 40 |
28496348 | Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus. | 2017 |
1 |
| 41 |
28588816 | Diabetic ketoacidosis inducing myocardial infarction secondary to treatment with dapagliflozin: a case report. | 2017 Jun |
2 |
| 42 |
28589154 | Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin. | 2017 Apr-Jun |
2 |
| 43 |
26835799 | The changing therapeutic armamentarium for patients with type 1 diabetes. | 2016 Apr |
1 |
| 44 |
26078479 | Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. | 2015 Sep |
1 |
| 45 |
26086329 | SGLT2 Inhibitors May Predispose to Ketoacidosis. | 2015 Aug |
1 |